<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have shown that the cyclin-dependent kinase inhibitor (CDKI) genes p15INK4B and p16INK4A are frequently inactivated by genetic alterations in many <z:mp ids='MP_0002018'>malignant tumors</z:mp> and that they are candidate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressor genes </plain></SENT>
<SENT sid="1" pm="."><plain>Although genetic alterations in these genes may be limited to lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, it has been reported that their inactivation by aberrant methylation of 5' CpG islands may be involved in various <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we investigated the p15INK4B and p16INK4A genes to clarify their roles in the pathogenesis of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Southern blotting analysis showed no gross genetic alterations in either of these genes </plain></SENT>
<SENT sid="4" pm="."><plain>However, hypermethylation of the 5' CpG island of the p15INK4B gene occurred frequently in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (16/32 [50%]) </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, the p15INK4B gene was frequently methylated in patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>], <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t], and overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> evolved from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 14/18 [78%]) compared with patients with low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> [RA] and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with ring sideroblast [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>]; 1/12 [8%]) </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, methylation status of the p15INK4B gene was progressed with the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in most patients examined </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, none of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients showed apparent hypermethylation of the p16INK4A gene </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that hypermethylation of the p15INK4B gene is involved in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and is one of the important late events during the development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>